Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SB Biomarker response: Diranersen is the first tau-directed therapy […]


7 h.
Science
ID: -3104896161302492907


Similar News expand_more


Science
Science
Science
Science
Science
Science
Science
Space
Technology
Technology
Entertainment
Technology
Science
Technology
Science
Science
Technology
Entertainment
Technology
Sport
Technology
Culture
Technology
Science
Science
Science
Science
Entertainment
Technology
Real Estate
Entertainment
Science
Crime
Technology
Science
Real Estate
Economics
Sport
Science
Travel
Culture
Technology
Military
Sport
Sport
Science
Entertainment
Science
Education
Popular countries based on strong economic and political relations

Add Watch Country

arrow_drop_down